Introduction
The surgical creation of arteriovenous circuits, including autogenous arteriovenous fistulas (AVFs) and prosthesis arteriovenous grafts (AVGs), is widely recognized as a standard of choice for hemodialysis access over the usage of central venous catheters (CVCs), which have high complication rates.
Methods

Study patients
Between January 2008 and May 2016, all patients with AVG and AVF dysfunction and treated with Viabahn stent placement were evaluated in a single-institution retrospective review.
Medical charts and laboratory databases were reviewed to collect demographic, clinical and instrumental data. Patients were followed for at least 180 days after the procedure, including assistance in the dialysis unit, telephone interview, and scheduled color-Doppler ultrasound examination at 1, 3 and 6 months after discharge. Long-term follow-up of hemodialysis access was monitored through clinical observation by nephrologists. In case of clinical abnormality (e.g., no thrill or lowpressure profile) a color-Doppler was promptly performed.
According to institutional guidelines on the retrospective collection and analysis of data, no institutional review board approval was required for this study. A written informed consent for the procedure was obtained from each patient. Table I shows characteristics of patients, AVFs and AVG lesions. Of the 37 patients, 62% were males, with a median age of 71 years (interquartile range [IQR] : 55-79 years).
Every patient underwent hemodialysis for end-stage renal disease. Significant comorbidities such as hypertension (97%), diabetes (30%), vascular disease (coronary, cerebral or peripheral; 65%) and smoking (38%) affected these patients. Furthermore, 28 (76%) patients received antiplatelet therapy with aspirin or clopidogrel.
Lesion lengths ranged from 2 to 17 cm. The median age of the fistula, intended as the interval between the creation of the hemodialysis shunt and the first stent placement, was 22.6 months (IQR: 7-46 months). Moreover, median followup was 22 months (IQR: 8.5 months; 30.7 months).
Definitions
Hemodialysis shunt dysfunction was identified using the following three criteria: clinical abnormality, access difficulty during dialysis, and abnormal color Doppler evaluation. Clinical abnormality included impaired physical examination (edema, no clinical detection of thrill, water-hammer pulsatility and low-pressure profile), difficult vein puncture, prolonged bleeding at puncture sites, no maturation after 3 months and pain of the upper limb. Access difficulty was defined as inability to obtain a dialysis blood pump flow rate ≥300 mL/min in two consecutive dialysis sessions. Abnormal color Doppler evaluation was defined as the presence of stenosis >50% of the feeding artery or outflow vein, a flow rate <500 mL/min and a resistance index >0.55 in the feeding artery.
Indications for stent placement were circuit thrombosis, venous out-flow occlusion, complex stenoses (residual stenosis >50%, acute recoil or vein rupture after angioplasty), recurrent stenoses (≥3 angioplasty within 6 months) and pseudoaneurysm.
Arterial stenoses, arterial-graft anastomosis, evidence of infection and severe iodinated contrast agent allergy were considered stenting procedure contraindication. There was no predefined limitation on lesion length. Venous anastomosis Cephalic, n (%) 26 (70) Basilic, n (%) 10 (27) Axillary, n (%) 1
Stent site Cephalic outflow, n (%) 29 (58) Basilic outflow, n (%)
11 ( The study outcomes were procedural and clinical success and stent patency intended as primary circuit patency (PP), target lesion primary patency (TLPP), assisted primary patency (APP) and secondary patency (SP).
Moreover, the analysis of risk factors for hemodialysis dysfunction that required a further endovascular procedure (angioplasty, thrombo-aspiration and a second Viabahn stent placement) was performed. Loss of circuit primary patency was defined as any reintervention.
A subgroup analysis was conducted to assess the efficacy of HBS Viabahn stent to treat peripheral venous long segment obstruction (LSO), defined as a length of total obstruction of the outflow vein at least of 70 mm that causes symptoms lasting more than 30 days (swelling of the arm, excessive pain and bleeding during hemodialysis session), hemodialysis dysfunction, and require an endo-bypass procedure.
Study outcomes were defined according to the recommendations of the SIR Technology Assessment Committee (4).
Procedural success was defined as less than 30% residual stenosis after endovascular stent procedure with continuity of the access circuit and without dissection or venous rupture.
Clinical success was defined as the ability to provide uninterrupted hemodialysis achieving a flowrate ≥300 mL/min for at least three consecutive sessions using the same access.
Primary circuit patency was the time from stent procedure until first intervention anywhere in the hemodialysis circuit or access circuit thrombosis.
Primary target lesion patency was the time from initial stent placement until repeat intervention performed at the area 5 mm proximal to, within, or 5 mm distal from stent-graft or access circuit thrombosis.
APP was the time from initial stent placement until thrombosis of the vascular access.
SP was the time from initial stent placement until the graft was abandoned or underwent surgical revision or mechanical thrombectomy and pharmacological thrombolysis (5). Multiple repetitive interventions can be included in SP.
The following 13 different variables were evaluated as potential risk factors for hemodialysis dysfunction that required reintervention: gender, patient age, hypertension, diabetes that required antihyperglycemic therapy, current smoking, peripheral and cardiovascular disease, ongoing antiplatelet therapy, type of fistula (AVF or AVG), site of fistula in the upper limb (proximal or distal), access age (from surgical creation to first stent placement), thrombosis of the whole circuit, juxta-anastomotic lesion (<2 cm from surgical anastomosis), peripheral venous LSO.
Procedure
At our division, any hemodialysis access dysfunction that required a stent placement into peripheral venous circuit was treated with HBS Viabahn stent-graft due to the HBS potential to reduce thrombotic risk, platelet aggregation, and neointimal hyperplasia compared with not coated expanded polytetrafluoroethylene stents and bare metal stents (6) .
Generally, through an introducer sheath, a 5-Fr Vertebral hydrophilic 1 Catheter (Terumo, Tokyo, Japan) and a 0.035", 180-cm long angled floppy hydrophilic guide wire (Terumo) were used to cross the lesion. The hydrophilic guidewire was exchanged for a 0.018" guidewire Thruway TM (Boston Scientific, Natick, Mass) that was used for stent deployment.
In case of LSO of venous out-flow, an adequate puncture site for hemodialysis was ensured prior to placement (Fig. 1) .
AVG or AVF with LSO were treated with peripheral venous LS recanalization procedure before stent placement.
The indications for endovascular treatment of LSO were: occlusion of venous superficial circulation with venous drainage redistributed into the deep circulation with swelling of the arm, excessive pain and bleeding during hemodialysis session and dysfunction of AVF/AVG; inability to perform the surgical creation of a new and more proximal hemodialysis access.
In our series venous out-flow obstruction affected the cephalic vein (n = 10) and the basilic vein of the arm (n = 1).
In patients with AVF or AVG, access was achieved by the anterograde puncture of the efferent vein and it was engaged with short 4 Fr introducer sheath. After venography, the LSO was crossed using 0.018"/0,014" guidewire (the following are ideal: Thruway TM and ChoICE TM , Boston Scientific, Natick, Mass) and 2.7 Fr hydrophilic microcatheter (Progreat, Terumo, Tokyo).
Once the lesion had been crossed, pre-dilatation with 2-or 3-mm diameter balloon catheter (Pacific Plus, Medtronic, Minneapolis, Minnesota) was subsequently performed to allow the passage of the delivery system.
If the obstruction segment was crossed by 0.014" guidewire, it was replaced by 0.018" guidewire.
The 4 Fr short introducer sheath was then changed for a short introducer sheath with profile ranged from 6 Fr to 8 Fr, depending on stent diameter that was selected according to the diameter of the adjacent normal reference vessel. The stent oversizing with target vessel should be avoided.
After completion of angiography, a second angioplasty with a recommended balloon diameter for device was used to touch up the stent-graft.
If the lesion could not be crossed, a second retrograde access was required through the puncture of the venous outflow, slightly more proximal to the obstruction.
Repeat procedures
Patients underwent a mean of 2.4 interventional procedures for hemodialysis access dysfunction. A total of 88 secondary endovascular interventions were performed, of
Statistical analysis
Categorical data are presented as frequencies and percentages and continuous data as median and IQR. KaplanMeyer curves were used to determine patencies and the log-rank test was used to test for differences between curves. During the follow-up, participants were censored because of death related to other causes with functioning access, renal transplantation, switch to peritoneal dialysis, or loss to follow-up. To assess risk factors for hemodialysis dysfunction that required reintervention after stent placement, a univariable Cox proportional hazards model was used to identify variables associated with the outcome and a multivariable Cox regression, including variables with p value <0.1 was carried out using a stepwise backward procedure employing the R algorithm based on the Akaike information criterion (estimation) at each step. The significance level was set to p<0.05. All the analyses were performed using the R Statistical Software (version 3.2.2; R foundation for Statistical Computing, Vienna, Austria).
Results
Over the study period, 37 consecutive patients underwent 50 HBS Viabahn stent-graft placements. A single stent-graft was deployed in 27 patients, 2 stent grafts were implanted in 10 patients and 3 devices were placed in 1 patient.
A single patient with LSO was treated with overlapping stent that was considered as single stent in the statistical analysis.
Table II provides patency rates in detail. The overall Kaplan-Meyer PPs were 60% and 42% at 12 and 24 months, respectively. Overall TLPP estimated rates were 68% and 49% at 12 and 24 months, respectively. The corresponding SP rates were 85% and 78% at the same period ( Fig. 2A, B, D) .
Procedural and clinical success rates for the index procedure were both 98% (49/50 procedures).
The sites of stent graft placement were: across the venous anastomosis of AVG (n = 10); in the cephalic vein outflow APP = assisted primary patency; AVF = arteriovenous fistula; AVG = arteriovenous graft; LSO = long segment obstruction; PP = primary circuit patency; SP = secondary patency; TLPP = target lesion primary pate.
excluding the cephalic arch (n = 26); within the cephalic arch (n = 3); in the basilic vein outflow (n = 11). A subgroup analysis of TLPP was performed regrouping the sites of stent placement as cephalic vein outflow, basilic vein outflow and graft venous anastomosis. Estimated TLPP rates at 12 months were 74% for stent placement at venous outflow (basilic and cephalic vein) and 48% for graft venous anastomosis ( Fig. 2E-F) . TLPP was statistically higher for both venous outflow than graft venous anastomosis (p = 0.0437) while no differences comparing the cephalic and basilic vein outflow (p = 0.732).
Venous anastomoses were created surgically on cephalic vein (70%), basilic vein (27%) and axillary vein (3%), and the site of the fistula in the upper limb was proximal or distal in 16 and 21 patients, respectively. Hemodialysis shunts were classified as: radiocephalic AVF (n = 22); brachiocephalic AVG (n = 4); brachiobasilic AVG (n = 10); brachioaxillary AVG (n = 1).
Patients were then segregated into two groups based on hemodialysis circuit type: 15 AVG and 22 AVF.
PP rates at 12 months after stent placement were 71% for AVF and 46% for AVG. The corresponding SP rates were 95% for AVF and 71% for AVG (Fig. 2G-H) .
PP and SP rates were significantly greater for AVF group rather than AVG group (p = 0.0165 and p = 0.00575).
Eleven patients presented peripheral LSO. Estimated PP rates at 12 and 24 months for stent placement after peripheral venous long segment recanalization procedure were 53% and 31%, respectively (Fig. 2I) . SP rates were 82% and 68%, respectively (Fig. 2L) . Stent-graft size ranged from 5 mm to 9 mm.
In our series, 23 patients underwent multiple endovascular procedures after the stent placement in the whole period of follow-up. The endovascular procedures included angioplasty, thrombo-aspiration and a second Viabahn stenting. The APP rates were 79% at 12 months and 61% at 24 months (Fig. 2C) .
At univariable Cox regression analysis, factors associated with reduced circuit primary patency were female sex (HR 2.97. 95% CI 1.27-6.96, p = 0.012), AVG (HR 2.75, 95% CI 1.17-6.46, p = 0.0204), proximal site of hemodialysis shunt (HR 2.73, 95% CI 1.16-6.44, p = 0.0215), access age (HR 0.98, 95% CI 0.96-1, p = 0.0478) and the presence of thrombosis before the stenting procedure (HR 3.014, 95% CI 1.29-7.03, p = 0.107) (Tab. III).
The final multivariable model confirmed the following variables as predictors of reintervention after stent placement: Female sex (HR 2.7, 95% CI 1.1-6.5, p = 0.0285), access age (HR 0.98, 95% CI 0.96-1, p = 0.0759) and thrombosis (HR 2.56, 95% CI 1.08-6.1, p = 0.0337) (Tab. III).
Three complications occurred: minor complications included two access hematoma that were conservatively managed with no consequences on hemodialysis circuit. A single case of infection of AVG by Staphylococcus aureus occurred three months after the stent placement. One procedure was unsuccessful because the circuit thrombosis occurred two days after the stent placement and the hemodialysis access was abandoned.
Discussion
Percutaneous transluminal angioplasty (PTA) still remains the primary treatment for dysfunctional AVF/AVG and the National Kidney Foundation -Kidney Disease Outcome Quality Initiative (KDOQI) -expected a primary circuit patency Patency results in the group of stent placement divided for cephalic and basilic venous outflow and graft anastomosis as Kaplan-Meier survival curves with log-rank test to test for differences between curves. TLPP at 6, 12 and 24 months of follow-up period (E-F). Patency results in the group of stent placement in patients with AVF and AVG as Kaplan-Meier survival curves with log-rank test to test for differences between curves. PP and SP at 6, 12, 24 months of follow-up (G-H). Patency results in the group of stent placement after peripheral LSO recanalization for each endpoint as Kaplan-Meier survival curves. PP (I) and SP (L) at 6, 12 and 24 months of follow-up period. APP = assisted primary patency; AVF = arteriovenous fistula; AVG = arteriovenous graft; LSO = long segment obstruction; PP = primary circuit patency; SP = secondary patency; TLPP = target lesion primary pate. at 6 months of 50% for stenosis without thrombosis and a primary circuit patency at 3 months of 40% for stenosis with thrombosis (7).
However, a number of studies evaluated the PTA primary circuit patency that is lower than KDOQI expectation and varied between 23% and 35% at 6 months (8, 9), so the stenting procedure after angioplasty is increased due to higher primary and secondary patency rather than angioplasty alone (8) .
Many stent types are used for the endovascular treatment of AVG/AVF, including bare metal stent, such as the SMART stent, and expanded polytetrafluoroethylene-covered (ePTFE) stents, as Fluency stent, Flair stent and GORE Viabahn Endoprosthesis with PROPATEN Bioactive Surface.
Bare metal stents were the first to be used, but the outcome was similar to angioplasty and they were gradually dismissed (10, 11) . The diffuse in-stent restenosis was the common mode of hemodialysis access failure (12) and Chan et al (13) reported an AVG primary patency of 25% at 6 months for SMART stent placement and an AVF primary assisted patency that did not differ significantly between the stent and angioplasty groups (13) .
Regarding the ePTFE-covered stents, no agreement has been defined as the best device among them.
Haskal et al (8) in a prospective, randomized multicenter trial, described a PP and TLPP after Flair stent placement at the graft-vein anastomosis at 6 months of 38% and 51%, respectively, with a procedural success of 94% (8) .
Into another study, Karnabatidis et al (14) analyzed the TLPP of fluency stents placed at anastomotic and venous outflow stenoses in recurrently failing prosthetic AVGs and demonstrated results of 61.4% with procedural success of 100%.
The procedural and clinical success rates achieved in this study for all dysfunctional accesses was 98%; that is in accordance with other studies regarding stent graft deployment (90%-100%) (15) .
The difference between our overall SP (85%) and APP (79%) rates and PP (60%) rates suggest that the endovascular management allows a long-term lifespan of fistulas even though the dysfunction of hemodialysis access occurred relatively early.
These results are in line with other published data on stent-graft use and seem to convey overall improved patency when compared to previously published data on bare metal stents and venoplasty (16, 17) .
In this study, complex stenoses and occlusions are most frequently located at cephalic and basilic venous out-flow, either for AVF as for AVG, and at the venous anastomosis of AVG in accordance with literature (18) .
Patients with AVFs treated with Viabahn stents showed a better outcome than patients with AVGs. AVF is the firstline approach for hemodialysis access due to longer PP, even if AVG had a short maturation period and high response to thrombectomy procedure (19, 20) .
Eleven patients with LSO of venous outflow, were treated with peripheral venous long segment recanalization procedure before stent placement. This complex treatment represented the last attempt to rescue an AVF/AVG that would otherwise be abandoned with subsequent CVC insertion. In particular, angioplasty was not a viable alternative treatment due to poor patency in extensive lesions (21) and the surgical creation of more proximal hemodialysis access was not possible for lack of venous circuit. The stent placement after recanalization of LSO is able to reduce the high venous pressure of the hemodialysis circuit solving edema, pain, excessive bleeding during hemodialysis session and delaying circuit thrombosis of dysfunctional AVFs and AVGs. In the literature, long segment recanalization before stent deployment is described only for central venous stenosis (22) and we adapted the endovascular procedure to the peripheral venous circuit of the upper limb. PP (53%) and SP (82%) of the stent placed after peripheral venous long segment recanalization was very high and is consistent with the overall PP and SP.
In this study, we also assessed 13 parameters that could negatively influence the outcome of stent placement; female sex, access age and thrombosis are predictors of reduced primary patency. In particular, the stent placement after long segment recanalization of peripheral venous outflow, was included in the Cox analysis and it did not result in a prognostic factor for multiple endovascular procedures.
Women had an increased risk of repeated interventions compared with men, probably driven by the combination of their post-menopausal age and surgical creation of AVG in 11 of 14 women.
Previous studies have documented that women of elderly age presented a higher platelet reactivity and a reduced response to dual-antiplatelet therapy that favored in-stent restenosis and thrombosis (23); moreover, arteriovenous graft is associated with inferior longevity of the hemodialysis access compared with autogenous arteriovenous fistula (24) .
Hemodialysis fistulas have a limited lifespan and are subject to many complications caused by repetitive punctures, and long-lasting hemodialysis accesses have already suffered frequent endovascular interventions prior to stent placement. With this background, our analysis confirms that access age seems to be a risk factor for reduced primary patency.
Also, thrombosis has been associated with an adverse impact on primary patency. It was the initial presentation in 11 of 15 AVG failures, while it was present in only 4 of 22 AVF dysfunctions.
The AVG surgical creation was performed at the elbow into 14 patients and probably this site exposed the graft and the venous outflow to chronic trauma caused by arm flexion, which could induce mechanical narrowing with subsequent stenosis and residual low flow. In this scenario, we maintain that the Viabahn stent is more flexible than other devices and adapts itself better to complex anatomy such as the antecubital fossa and the cephalic arch (25, 26) .
Our study showed that HBS Viabahn stent is able to retain patency into AVF and AVG and its use is helpful especially in cases of complex anatomy and LSO of venous outflow.
Limitations
Our study design was retrospective and did not compare the patency of stent grafts with other endovascular procedures to treat malfunctioning hemodialysis access such as PTA alone, ultra-high-pressure PTA, cutting balloon and PTA with drug eluting balloon.
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